Losartan for the nephropathy of sickle cell anemia: A phase-2, multicenter trial

American Journal of Hematology

Volumn 92, Issue 9, 2017, Pages E520-E528

  Quinn, Charles T ^a   Saraf, Santosh L ^b   Gordeuk, Victor R ^b   Fitzhugh, Courtney D ^c   Creary, Susan E ^d   Bodas, Prasad ^e   George, Alex ^f   Raj, Ashok B ^g   Nero, Alecia C ^h   Terrell, Catherine E ^a   McCord, Lisa ^a   Lane, Adam ^a   Ackerman, Hans C ^c   Yang, Yu ^c   Niss, Omar ^a   Taylor, Michael D ^a   Devarajan, Prasad ^a   Malik, Punam ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d NATIONWIDE CHILDREN S HOSPITAL   (United States)

^e AKRON CHILDREN'S HOSPITAL   (United States)

^f TEXAS CHILDREN S HOSPITAL   (United States)

^g UNIVERSITY OF LOUISVILLE   (United States)

^h UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 N,N' DIMETHYLARGININE; ALBUMIN; ALPHA AMINO ACID; ARGININE; CREATININE; DIMETHYLARGININASE; HEMOGLOBIN; HYDROXYUREA; KIM 1 PROTEIN; LOSARTAN; MONOMETHYLARGININE; N(G),N(G) DIMETHYLARGININE; NAG PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ADULT; ALBUMINURIA; ANGIONEUROTIC EDEMA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DIASTOLIC DYSFUNCTION; DISEASE ASSOCIATION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; FUNCTIONAL STATUS; HEMOGLOBIN DETERMINATION; HUMAN; HYPERKALEMIA; KIDNEY DISEASE; LEG CRAMP; MACROALBUMINURIA; MALE; MICROALBUMINURIA; MULTICENTER STUDY; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SICKLE CELL ANEMIA; SINGLE DRUG DOSE; SYSTOLIC BLOOD PRESSURE; URINE OSMOLALITY; YOUNG ADULT; ADOLESCENT; AGE; ANEMIA, SICKLE CELL; CHILD; CLINICAL TRIAL; COMPLICATION; GLOMERULUS FILTRATION RATE; MIDDLE AGED; PATHOPHYSIOLOGY; URINE;

ADOLESCENT; ADULT; AGE FACTORS; ALBUMINURIA; ANEMIA, SICKLE CELL; CHILD; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; LOSARTAN; MALE; MIDDLE AGED;

EID: 85025081994     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24810     Document Type: Article

References (48)

1. Saborio P, Scheinman JI. Sickle cell nephropathy. J Am Soc Nephrol. 1999;10(1):187–192.
2. Becker AM. Sickle cell nephropathy: challenging the conventional wisdom. Pediatr Nephrol. 2011;26(12):2099–2109. doi:10.1007/s00467-010-1736-2.
3. Asnani M, Serjeant G, Royal-Thomas T, Reid M. Predictors of renal function progression in adults with homozygous sickle cell disease. Br J Haematol. 2016;173(3):461–468. doi:10.1111/bjh.13967.
4. Guasch A, Cua M, Mitch WE. Early detection and the course of glomerular injury in patients with sickle cell anemia. Kidney Int. 1996;49(3):786–791.
5. McPherson Yee M, Jabbar SF, Osunkwo I, et al. Chronic kidney disease and albuminuria in children with sickle cell disease. Clin J Am Soc Nephrol. 2011;6(11):2628–2633. doi:10.2215/CJN.01600211.
6. Dharnidharka VR, Dabbagh S, Atiyeh B, Simpson P, Sarnaik S. Prevalence of microalbuminuria in children with sickle cell disease. Pediatr Nephrol. 1998;12(6):475–478.
7. Pham PT, Pham PC, Wilkinson AH, Lew SQ. Renal abnormalities in sickle cell disease. Kidney Int. 2000;57(1):1–8. doi:10.1046/j.1523-1755.2000.00806.x.
8. Alvarez O, Montane B, Lopez G, Wilkinson J, Miller T. Early blood transfusions protect against microalbuminuria in children with sickle cell disease. Pediatr Blood Cancer. 2006;47(1):71–76. doi:10.1002/pbc.20645.
9. Guasch A, Navarrete J, Nass K, Zayas CF. Glomerular involvement in adults with sickle cell hemoglobinopathies: prevalence and clinical correlates of progressive renal failure. J Am Soc Nephrol. 2006;17(8):2228–2235. doi:10.1681/ASN.2002010084.
10. Wesson DE. The initiation and progression of sickle cell nephropathy. Kidney Int. 2002;61(6):2277–2286. doi:10.1046/j.1523-1755.2002.00363.x.
11. Guasch A, Cua M, You W, Mitch WE. Sickle cell anemia causes a distinct pattern of glomerular dysfunction. Kidney Int. 1997;51(3):826–833.
12. Falk RJ, Scheinman J, Phillips G, Orringer E, Johnson A, Jennette JC. Prevalence and pathologic features of sickle cell nephropathy and response to inhibition of angiotensin-converting enzyme. N Engl J Med. 1992;326(14):910–915. doi:10.1056/NEJM199204023261402.
13. Gosmanova EO, Zaidi S, Wan JY, Adams-Graves PE. Prevalence and progression of chronic kidney disease in adult patients with sickle cell disease. J Invest Med. 2014;62(5):804–807. doi:10.1097/01.JIM.0000446836.75352.72.
14. Powars DR, Elliott-Mills DD, Chan L, et al. Chronic renal failure in sickle cell disease: risk factors, clinical course, and mortality. Ann Intern Med. 1991;115(8):614–620.
15. Abbott KC, Hypolite IO, Agodoa LY. Sickle cell nephropathy at end-stage renal disease in the United States: patient characteristics and survival. Clin Nephrol. 2002;58(1):9–15.
16. McClellan AC, Luthi J-C, Lynch JR, et al. High one year mortality in adults with sickle cell disease and end-stage renal disease. Br J Haematol. 2012;159(3):360–367. doi:10.1111/bjh.12024.
17. 2R and cytoskeletal dysregulation. Nat Commun. 2015;6:5914. doi:10.1038/ncomms6914.
18. Roy S, Konstantinidis DG, Rizvi T, et al. Increased oxidative stress in sickle cell disease activates the renin-angiotensin-TGF-β pathway to mediate sickle nephropathy. Blood. 2013;122(21):2211–2211.
19. Aoki RY, Saad ST. Enalapril reduces the albuminuria of patients with sickle cell disease. Am J Med. 1995;98(5):432–435. doi:10.1016/S0002-9343(99)80341-6.
20. Foucan L, Bourhis V, Bangou J, Mérault L, Etienne-Julan M, Salmi RL. A randomized trial of captopril for microalbuminuria in normotensive adults with sickle cell anemia. Am J Med. 1998;104(4):339–342.
21. Fitzhugh CD, Wigfall DR, Ware RE. Enalapril and hydroxyurea therapy for children with sickle nephropathy. Pediatr Blood Cancer. 2005;45(7):982–985. doi:10.1002/pbc.20296.
22. McKie KT, Hanevold CD, Hernandez C, Waller JL, Ortiz L, McKie KM. Prevalence, prevention, and treatment of microalbuminuria and proteinuria in children with sickle cell disease. J Pediatr Hematol Oncol. 2007;29(3):140–144. doi:10.1097/MPH.0b013e3180335081.
23. Sasongko TH, Nagalla S, Ballas SK. Angiotensin-converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease. Cochrane Database Syst Rev. 2015;(6):CD009191. doi:10.1002/14651858.CD009191.pub3.
24. Siragy HM. The angiotensin II type 2 receptor and the kidney. J Renin Angiotensin Aldosterone Syst. 2010;11(1):33–36. doi:10.1177/1470320309347786.
25. Padia SH, Carey RM. AT2 receptors: beneficial counter-regulatory role in cardiovascular and renal function. Pflugers Arch. 2013;465(1):99–110. doi:10.1007/s00424-012-1146-3.
26. Wenzel UO, Krebs C, Benndorf R. The angiotensin II type 2 receptor in renal disease. J Renin Angiotensin Aldosterone Syst. 2010;11(1):37–41. doi:10.1177/1470320309347787.
27. Pylypchuk GB. ACE inhibitor- versus angiotensin II blocker-induced cough and angioedema. Ann Pharmacother. 1998;32(10):1060–1066. doi:10.1345/aph.17388.
28. DeBaun MR, Strunk RC. The intersection between asthma and acute chest syndrome in children with sickle-cell anaemia. Lancet. 2016;387(10037):2545–2553. doi:10.1016/S0140-6736(16)00145-8.
29. Datta V, Ayengar JR, Karpate S, Chaturvedi P. Microalbuminuria as a predictor of early glomerular injury in children with sickle cell disease. Ind J Pediatr. 2003;70(4):307–309.
30. Zandbergen AAM, Baggen MGA, Lamberts SWJ, Bootsma AH, de Zeeuw D, Ouwendijk RJT. Effect of losartan on microalbuminuria in normotensive patients with type 2 diabetes mellitus. Ann Intern Med. 2003;139(2):90–96.
31. Alkaitis MS, Nardone G, Chertow JH, Ackerman HC. Resolution and quantification of arginine, monomethylarginine, asymmetric dimethylarginine, and symmetric dimethylarginine in plasma using HPLC with internal calibration. Biomed Chromatogr. 2016;30(3):294–300. doi:10.1002/bmc.3548.
32. Tutarel O, Denecke A, Bode-Böger SM, et al. Symmetrical dimethylarginine outperforms CKD-EPI and MDRD-derived eGFR for the assessment of renal function in patients with adult congenital heart disease. Kidney Blood Press Res. 2011;34(1):41–45. doi:10.1159/000322614.
33. El-Khoury JM, Bunch DR, Hu B, Payto D, Reineks EZ, Wang S. Comparison of symmetric dimethylarginine with creatinine, cystatin C and their eGFR equations as markers of kidney function. Clin Biochem. 2016;49(15):1140–1143. doi:10.1016/j.clinbiochem.2016.07.009.
34. Luo Z, Teerlink T, Griendling K, Aslam S, Welch WJ, Wilcox CS. Angiotensin II and NADPH oxidase increase ADMA in vascular smooth muscle cells. Hypertension. 2010;56(3):498–504. doi:10.1161/HYPERTENSIONAHA.110.152959.
35. Lottenberg R, Hassell KL. An evidence-based approach to the treatment of adults with sickle cell disease. Hematology Am Soc Hematol Educ Program. 2005;2005(1):58–65. doi:10.1182/asheducation-2005.1.58.
36. Shatat IF, Qanungo S, Hudson S, Laken MA, Hailpern SM. Changes in urine microalbumin-to-creatinine ratio in children with sickle cell disease over time. Front Pediatr. 2016;4:106doi:10.3389/fped.2016.00106.
37. Allon M. Renal abnormalities in sickle cell disease. Arch Intern Med. 1990;150(3):501–504.
38. Sharpe CC, Thein SL. Sickle cell nephropathy - a practical approach. Br J Haematol. 2011;155(3):287–297. doi:10.1111/j.1365-2141.2011.08853.x.
39. Huang S-HS, Sharma AP, Yasin A, Lindsay RM, Clark WF, Filler G. Hyperfiltration affects accuracy of creatinine eGFR measurement. Clin J Am Soc Nephrol. 2011;6(2):274–280. doi:10.2215/CJN.02760310.
40. Voskaridou E, Terpos E, Michail S, et al. Early markers of renal dysfunction in patients with sickle cell/beta-thalassemia. Kidney Int. 2006;69(11):2037–2042. doi:10.1038/sj.ki.5000248.
41. Alvarez O, Zilleruelo G, Wright D, Montane B, Lopez-Mitnik G. Serum cystatin C levels in children with sickle cell disease. Pediatr Nephrol. 2006;21(4):533–537. doi:10.1007/s00467-006-0033-6.
42. Knight EL, Verhave JC, Spiegelman D, et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int. 2004;65(4):1416–1421. doi:10.1111/j.1523-1755.2004.00517.x.
43. Schepers E, Barreto DV, Liabeuf S, et al. Symmetric dimethylarginine as a proinflammatory agent in chronic kidney disease. Clin J Am Soc Nephrol. 2011;6(10):2374–2383. doi:10.2215/CJN.01720211.
44. Kielstein JT, Böger RH, Bode-Böger SM, et al. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol. 2002;13(1):170–176.
45. Niss O, Quinn CT, Lane A, et al. Cardiomyopathy with restrictive physiology in sickle cell disease. JACC Cardiovasc Imaging. 2016;9(3):243–252. doi:10.1016/j.jcmg.2015.05.013.
46. Bakeer N, James J, Roy S, et al. Sickle cell anemia mice develop a unique cardiomyopathy with restrictive physiology. Proc Natl Acad Sci USA. 2016;113(35):E5182–E5191. doi:10.1073/pnas.1600311113.
47. Sachdev V, Machado RF, Shizukuda Y, et al. Diastolic dysfunction is an independent risk factor for death in patients with sickle cell disease. J Am Coll Cardiol. 2007;49(4):472–479. doi:10.1016/j.jacc.2006.09.038.
48. Lima CSP, Ueti OM, Ueti AA, Franchini KG, Costa FF, Saad STO. Enalapril therapy and cardiac remodelling in sickle cell disease patients. Acta Cardiol. 2008;63(5):599–602. doi:10.2143/AC.63.5.2033227.